Global CDMO Reach NextPharma operates across multiple European centers (Germany, France, Finland, UK, Norway) and has expanded via acquisitions (Tampere facility, Santen acquisition, Lonza assets), indicating a broad footprint. Sales opportunity: position as a turnkey European CDMO partner for complex manufacturing, suite of dosage forms, and cross-border supply chain capabilities.

Diverse Dosage Forms Capabilities span solids, non-sterile and sterile liquids, semi-solids, and specialized containment for hormones, narcotics, beta-lactams, highly potent compounds, and clinical trial services. Sales opportunity: offer integrated development and manufacturing for diverse product lines, including high-containment and highly potent programs.

Strategic Partnerships Recent leadership and structural expansions signal a growth-oriented strategy and readiness for larger collaborations. Sales opportunity: pursue long-term CDMO partnerships for scale-up, tech platform investments, and joint development across pharma, nutraceutical, and biotech segments.

Tech-enabled Growth Technology stack includes SAP FICO, SAP SuccessFactors, Cognos, Azure, Jira, and analytics tooling, highlighting strong ERP, HR, and data capabilities. Sales opportunity: emphasize robust quality systems, data-driven manufacturing, and scalable IT infrastructure as a differentiator for complex projects.

Financial and Market Position Revenue range of $250M-$500M with funding support around $40M, placing NextPharma as a mid‑cap CDMO with capital to invest in capacity and capabilities. Sales opportunity: propose capacity expansion, technology upgrades, or new site certifications to capture more of Europe’s contract manufacturing demand.